King buys Elan drugs

- Last updated on GMT

Related tags: Puerto rico, United states

King Pharmaceuticals is to buy the rights to two of Elan Corp.'s
drugs in the United States and Puerto Rico for $850 million.

King Pharmaceuticals is to buy the rights to two of Elan Corp.'s drugs in the United States and Puerto Rico for $850 million.

The purchase includes insomnia treatment Sonata and muscle relaxant Skelaxin, rights to potential new formulations of these products, and Elan's primary care field sales force of more than 400 representatives.

In a press release, Bristol-based King said the acquisition of the Irish pharmaceutical company's unit will add to its earnings upon closing, and noted Sonata and Skelaxin had 2002 sales of about $238 million in the United States and Puerto Rico.

Under the agreement, King will reimburse Elan for the costs of developing new formulations of Sonata, and potentially pay Elan more than $70 million upon achievement of certain milestones, including regulatory approval.

Related news

Related products

show more

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

LACTIUM®: dairy bioactive to soothe your pet

LACTIUM®: dairy bioactive to soothe your pet

Ingredia | 12-Oct-2021 | Infographic

Lactium® gives you the chance to better meet your pet’s needs for a more harmonious life together. Lactium® acts on the brain and has no side-effects,...

Related suppliers

Follow us

Products

View more

Webinars